The Optum-backed medical consumer engagement platform increased its total funding to $256m in a round valuing it at $1.6bn.
US-based patient engagement software provider Truepill, which counts healthcare provider Optum as a backer, closed its series D round at $142m yesterday, bringing its total funding to $256m.
Investment advisory firm TI Platform Management and Initialized Capital provided the series D funding at a valuation of $1.6bn.
Truepill has developed a software platform used to help healthcare providers communicate with their customers for a range of services such as diagnostics, pharmacy and telehealth.
The company plans to use the funding…
